Deal volume and value increase in the quarter while fundamentals and pending deals point to potential for heightened activity in the fourth quarter of 2013. Total deal volume increased approximately 10% during the third quarter of 2013 in comparison with the second quarter of 2013, while declining by approximately the same amount relative to the third quarter of 2012. Deal value increased by nearly 50% over the previous quarter while declining approximately 15% relative to the third quarter of 2012. The increase in the third quarter owes primarily to two large transactions in the medical device segment.
This issue of Pharmaceutical and Life Sciences Deals Insights Quarterly brings you PwC’s perspective on deal activity in the industry and features the following:
Market update: A summary of M&A deals and trends for the previous quarter.
Country spotlight: An update on doing deals in selected geographies. This issue focuses on Russia. While traditionally known for its natural resources, Russia has begun to shift its focus to more effectively integrate into global trade and investment transactions and develop its market economy.
Strategy corner: A feature offering tips and insight on different aspects of deal making. This issue focuses on recent trends in the use of earn-outs, seller financing, and structured transactions and spotlight practical considerations.